Abbildung 1: coBRIM-Studie: Medianes Gesamtüberleben bei Patienten mit fortgeschrittenem
malignen Melanom unter der Kombinationstherapie Cobimetinib plus Vemurafenib
versus Vemurafenib-Monotherapie (mod. nach 4, 5)
abb-1-roche-symposium
This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.